Co-Diagnostics, Inc. （CODX） Overview
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Co-Diagnostics Launches New Equity Distribution Agreement
On October 20, 2025, Co-Diagnostics, Inc. entered into an Equity Distribution Agreement with Maxim Group LLC to establish an at-the-market equity program, allowing the company to offer and sell up to $10 million of its common stock. This move comes after the company terminated a previous agreement with Piper Sandler & Co. and Clear Street LLC, effective September 30, 2025. The new agreement provides flexibility in selling shares, but there is no obligation for the company to sell any shares, and the offering will conclude once the $10 million threshold is reached or the agreement is terminated.
The most recent analyst rating on （CODX） stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.
Spark’s Take on CODX Stock
According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.
Co-Diagnostics faces significant financial challenges, with declining revenues and profitability being the most impactful factors. Technical analysis provides mixed signals, with short-term bearish momentum but some medium-term support. Valuation metrics are unattractive due to negative earnings. Despite some positive developments in product advancement and grant support, the financial difficulties weigh heavily on the overall score.
CODX Stock: What’s Driving The Super Rally?
Shares of Co-Diagnostics （CODX） more than doubled in Monday morning trading following news of a joint venture with Arabian Eagle Manufacturing.
CODX’s stock was up more than 148% in the morning trade with retail interest on Stocktwits jumping to ‘extremely bullish’ from ‘bearish’ territory as chatter accelerated from ‘low’ to ‘extremely high’ levels over the past day.
The newly formed joint venture, CoMira Diagnostics, will focus on researching, developing, manufacturing, and distributing Co-Diagnostics’ molecular diagnostic technologies. This includes a new PCR point-of-care platform designed to deliver faster, cost-effective, and reliable diagnostics for hospitals, clinics, and healthcare providers across Saudi Arabia and 18 additional Middle East and North Africa （MENA） countries.
The company said Arabian Eagle brings regional regulatory expertise, logistics capabilities, and local operational support, while Co-Diagnostics provides the core technology and product development. Co-Diagnostics said the partnership enables local production, accelerating access to testing while lowering costs and improving turnaround times for healthcare providers.